Profit before exceptional items and tax rose to ₹450 crore in Q4FY26 from ₹333 crore a year ago. Revenue for the quarter increased 6.3% year-on-year to ₹2,388.5 crore, while EBITDA rose 12.7% to ₹484 crore.
Operating margin improved to 20.2% from 19% in the corresponding quarter last year, reflecting better operational performance across businesses.
The company said income from Indian formulations business rose 12% year-on-year to ₹853.33 crore during the quarter. Export income also registered healthy growth, increasing 9% to ₹845.53 crore.
The Board recommended a dividend of ₹6 per share of face value Re 1 each for FY26. The proposed dividend is subject to shareholder approval at the ensuing annual general meeting. The company has fixed August 7, 2026 as the record date for determining shareholder entitlement to the dividend.
Ipca Laboratories also said its Board approved the re-appointment of Prashant Godha as Executive Director for a further term of five years with effect from August 16, 2026, subject to shareholder approval.
Also Read: Aegis Logistics Q4 Results: Stock jumps 8% on strong profit, revenue growth; Margins stable
The company described itself as a fully integrated pharmaceutical player with a strong export focus, manufacturing both finished dosage formulations and active pharmaceutical ingredients (APIs).
Ahead of the earnings announcement, shares of Ipca Laboratories were trading marginally lower at ₹1,570.10 on the NSE.
First Published: May 29, 2026 2:17 PM IST
